Increase in serum levels of phosphatidylserine-specific phospholipase A_(1) in COVID-19 patients

作     者：Takuya Shimura Makoto Kurano Koh Okamoto Daisuke Jubishi Kuniyuki Kano Koji Igarashi Satoshi Shimamoto Junken Aoki Kyoji Moriya Yutaka Yatomi 

作者机构：Department of Clinical LaboratoryThe University of Tokyo HospitalTokyoJapan Department of Clinical Laboratory MedicineGraduate School of MedicineThe University of TokyoTokyoJapan Department of Infectious DiseasesThe University of Tokyo HospitalTokyoJapan Department of Health ChemistryGraduate School of Pharmaceutical SciencesThe University of TokyoTokyoJapan Bioscience DivisionTOSOH CorporationKanagawaJapan 

出 版 物：《Cellular & Molecular Immunology》 (中国免疫学杂志（英文版）)

年 卷 期：2021年第18卷第9期

页      面：2275-2277页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：This work was supported by Research Grants in the Natural Sciences from the Mitsubishi Foundation(MK) Leading Advanced Projects for medical innovation(LEAP)from AMED(JA and YY) 

主　　题：drugs inflammation acute 

摘      要：The development of novel drugs to overcome the current global coronavirus disease 2019(COVID-19)pandemic caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is an important *** antiviral agents have been investigated,one of the important goals of treatment is also to control the biological response to the infection.A series of elegant basic studies have revealed that lysophosphatidylserine(LysoPS)might play important roles in inflammation through three kinds of G protein-coupled receptors[1];LysoPS reportedly suppresses activation of T cells[2]and secretion of inflammatory cytokines from macrophages[3]and promotes phagocytosis of apoptotic cells,including apoptotic neutrophils,by macrophages[4].